Biotest AG and Lonza Enter into Manufacturing Agreement
Biotest AG and Lonza have concluded a manufacturing agreement in January 2005 for further production of GMP grade consistency batches of Biotest´s monoclonal antibody BT-061. The production, which has already commenced this week supplies Biotest with material for further clinical studies. In addition, this agreement opens up the option on future large scale production with the technological leader Lonza.
BT-061 is directed against a novel target on T-cells mediating a unique, immunoregulatory mechanism of action. The candidate is Biotest´s most advanced monoclonal antibody and has shown tolerability and efficacy in early clinical trials in patients with rheumatoid arthritis. With the clinical material produced by Lonza Biologics, Slough, UK, development will continue in rheumatoid arthritis and psoriasis.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.